{"url_path":"/sec/igc/8-k/2026-07-06/item-3-02","section_key":"item-3-02","section_title":"Item 3.02 Unregistered Sales of Equity Securities.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-06","source_url":"https://www.sec.gov/Archives/edgar/data/1326205/0001185185-26-002808-index.html","accession_number":"0001185185-26-002808","cik":"0001326205","ticker":"IGC","issuer_name":"IGC Pharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1326205/0001185185-26-002808-index.html","primary_entity_key":"0001326205","primary_entity_name":"IGC Pharma, Inc."},"word_count":142,"has_tables":true,"body_markdown":"** **\n\n**Item 3.02 Unregistered Sales of Equity Securities.**\n\n \n\nThe information set forth\nin Item 1.01 is incorporated herein by reference. The shares of common stock were issued in private transactions in reliance on Section\n4(a)(2) of the Securities Act of 1933, as amended, as transactions by an issuer not involving any public offering. The recipients are\nexecutive officers of the Company and acquired the shares for investment purposes. No general solicitation was used, and no underwriting\ndiscounts or commissions were paid. The shares are restricted securities and may not be offered or sold absent registration under the\nSecurities Act or an available exemption from registration, including Rule 144. Any resale by Mr. Mukunda or Ms. Grimaldi will remain\nsubject to applicable securities law restrictions, Section 16 of the Securities Exchange Act of 1934, the Company’s insider trading\npolicy, and applicable NYSE American rules."}